Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.
There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times.
The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.
The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive.
The Glasgow-based emerging biopharma recently tapped veteran biotech leader Alan Walker as CEO as it moves ahead with two therapeutic candidates, an rIFN alpha14 focused on early-stage COVID-19 infection and a tick-derived Evasin targeting late-stage COVID-19 ARDS patients.
That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.
Biotechs are surging in Chile, fertilized by a deep academic foundation, ample funding, plentiful low-cost laboratory space, and a collaborative global research environment. We caught up with Cristian Hernandez-Cuevas, the man behind the mission.
We just launched the first full episode of the Business of Biotech podcast, a series purpose-built for the leaders of new and emerging biopharma companies. Here’s a recap of the first episode with industry icon Allan Shaw, highlighting the season to come and offering some strategic, straightforward advice for new biopharma leaders.